Novel Lupus Agent, a Success in Phase II Trial
Nov 09, 2020 AM EST
The phase II trial of a monoclonal antibody called BIIB059, which hinders the production of interferon type 1, exhibited effectiveness in patients who had active systemic lupus erythematosus or SLE.
